Skip to Content

Does Cinqair treat all types of asthma?

Answers (1)

Official Answer by 5 May 2016

No, Cinqair (reslizumab) from Teva Pharmaceuticals is not for initial asthma treatment, for less severe asthma, or for use as a rescue therapy.

Cinqair was FDA-approved in March 2016, and is used in more severe asthma with elevated eosinophils (a type of white blood cell) that has not responded well to initial treatments. Cinqair is an anti-interleukin-5 (IL-5) used in adults 18 years and older as an add-on therapy for the maintenance treatment of severe asthma in adults not well-controlled on their current asthma medications.

In studies, patients receiving Cinqair had fewer asthma attacks, a longer time to first attack, and improvement in lung functions tests. Common side effects with Cinqair include anaphylaxis (a severe, possibly life-threatening allergy), cancer, and muscle pain.

Votes: +0 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What is the difference between Biktarvy and Descovy?

Posted 7 Mar 2018 1 answerFAQ by

What is the difference between Symdeko and Orkambi?

Posted 7 Mar 2018 1 answerFAQ by